NASDAQ : VYGR
Voyager Therapeutics, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 1.76 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 108.45M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 105.98M |
| Enterprise Value | -10.26M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 61.62M |
| Shares Outstanding | 61.62M |
| Shares Change (YoY) | +2.13% |
| Shares Change (QoQ) | +1.77% |
| Owned by Insiders (%) | 1.13% |
| Owned by Institutions (%) | 44.71% |
| Float | 44.47M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3.08 |
| Forward PS | 4.20 |
| PB Ratio | 0.68 |
| P/TBV Ratio | 0.69 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 7.51 |
| Quick Ratio | 7.16 |
| Debt / Equity | 0.21 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -54.09% |
| Return on Assets (ROA) | -27.34% |
| Return on Invested Capital (ROIC) | -165.53% |
| Return on Capital Employed (ROCE) | -62.79% |
| Weighted Average Cost of Capital (WACC) | 8.65% |
| Revenue Per Employee | $244,390 |
| Profits Per Employee | -$764,028 |
| Employee Count | 141 |
| Asset Turnover | 0.13 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | 126,000 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.28 |
| 52-Week Price Change | -62.69% |
| 50-Day Moving Average | 2.71 |
| 200-Day Moving Average | 3.46 |
| Relative Strength Index (RSI) | 29.49 |
| Average Volume (20 Days) | 1,009,929 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 3.64M |
| Short Previous Month | 3.97M |
| Short % of Shares Out | 5.90% |
| Short % of Float | 8.18% |
| Short Ratio (days to cover) | 4.80 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 34.46M |
| Gross Profit | -81.60M |
| Operating Income | -113.69M |
| Pretax Income | -107.60M |
| Net Income | -107.73M |
| EBITDA | -109.87M |
| EBIT | -113.69M |
| Loss Per Share | -$1.81 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 116.34M |
| Total Debt | 32.57M |
| Net Cash | 116.25M |
| Net Cash Per Share | $1.89 |
| Equity (Book Value) | 154.38M |
| Book Value Per Share | 2.52 |
| Working Capital | 108.54M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -120.57M |
| Capital Expenditures | -847,000 |
| Depreciation & Amortization | 3.82M |
| Net Borrowing | n/a |
| Free Cash Flow | -121.42M |
| FCF Per Share | -$1.97 |
Margins
| Measure | Value |
|---|
| Gross Margin | -236.81% |
| Operating Margin | -329.92% |
| Pretax Margin | -312.26% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -2.13% |
| Shareholder Yield | -2.13% |
| Earnings Yield | -105.36% |
| FCF Yield | -114.56% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $14.89 |
| Price Target Difference | 765.70% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 11 |
| Revenue Growth Forecast (3Y) | 26.98% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -1.49 |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |